Comparative Pharmacology
Head-to-head clinical analysis: NAPHCON FORTE versus VASOCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPHCON FORTE versus VASOCON A.
NAPHCON FORTE vs VASOCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline acts as an agonist at alpha-adrenergic receptors in the vascular smooth muscle of the conjunctiva, causing vasoconstriction and reducing redness.
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
1-2 drops of 0.1% solution in the affected eye(s) every 3-4 hours as needed.
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life is 9-11 hours; clinically, steady state is reached after 2-3 days of regular dosing.
Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment.
Renal excretion of unchanged drug (65%) and metabolites (35%); less than 1% fecal.
Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites.
Category C
Category C
Ophthalmic Decongestant
Ophthalmic Decongestant/Antihistamine Combination